Parabilis Medicines, Inc.

424B4 priced

Price $20.00 · 33,500,000 shares · Gross proceeds $670,000,000

FWP supplemental

Price $20.00 · 33,500,000 shares · Gross proceeds $670,000,000

Parabilis Medicines, Inc. has priced its upsized initial public offering (IPO) of 33.5 million shares at $20.00 per share, with an additional 5.025 million shares available under an underwriters' option. The company also announced a concurrent private placement of 4.166 million shares to Regeneron Pharmaceuticals at $18.00 per share. The IPO, expected to close on June 11, 2026, will list Parabilis on Nasdaq under the ticker symbol PBLS. Underwriters include Leerink Partners, BofA Securities, Evercore ISI, and Guggenheim Securities.

EFFECT effective

CERT inactive

S-1/A amended

Range $17.00 to $19.00 · 33,333,334 shares

Parabilis Medicines, Inc.'s S-1/A filing highlights risks related to the development and regulatory approval of its product candidates, particularly zolucatetide. Key concerns include delays in clinical trials due to preclinical challenges, reliance on non-human primates (NHPs) for testing, and complexities in transitioning to an Injectable Formulation. The filing also emphasizes financial risks from restrictive debt covenants and uncertainties in obtaining regulatory approvals for foreign trial data. The company faces significant hurdles in demonstrating efficacy, managing clinical trial logistics, and navigating evolving regulatory requirements.

8-A12B effective

S-1/A amended

Price $18.00 · Range $17.00 to $19.00 · 25,000,000 shares · Gross proceeds $450,000,000

Parabilis Medicines, Inc. is a biotechnology company focused on developing novel therapies targeting cancer drivers and other diseases through innovative mechanisms. The filing highlights significant risks related to the development of its product candidates, including uncertainties in clinical trials, regulatory approvals, and financial constraints. The company emphasizes its reliance on third-party partners for research, manufacturing, and clinical trials, while also noting challenges in managing growth and maintaining competitive advantages.

S-1/A amended

Parabilis Medicines, Inc. has filed an S-1/A amendment to its IPO registration, primarily adding exhibits. The company, focused on developing novel therapeutics for cancer and fibrotic diseases, outlines its business model, product pipeline, and risk factors. The amendment reflects updates to regulatory disclosures and exhibits, with no substantive changes to core financial or operational details.

S-1 filed

Parabilis Medicines, Inc. is advancing novel therapeutics targeting cancer driver targets with unique mechanisms, but faces significant risks in development, regulatory approval, and commercialization. The company highlights challenges in preclinical and clinical trials, reliance on third-party partners, financial constraints, and uncertainties in achieving development milestones. Its S-1 filing underscores the high-risk, high-reward nature of its pipeline, including zolucatetide for desmoid tumors, while emphasizing the potential for delays, increased costs, and regulatory hurdles.

CONFIDENTIAL-S1 filed

Parabilis Medicines moved from a confidential draft S-1 dated April 2, 2026 to a public S-1 filing on May 19, 2026, with Reuters and Renaissance Capital both covering the IPO launch and Renaissance explicitly tying it to the earlier confidential submission.

DRS filed